May 5, 2017

Pfizer Inc. and Domain Therapeutics enter into a collaboration agreement on bioSensAll™

Proprietary technology will be used to profile signaling of mutant GPCRs in order to improve and accelerate the validation of novel GPCR drug targets

Strasbourg, France, and Montreal, Canada, April 25, 2017 – Domain Therapeutics, a France- and Quebec-based biopharmaceutical company specializing in the research and development of new drug candidates that target G protein-coupled receptors (GPCRs), today announced a collaboration agreement with Pfizer Inc. (Pfizer; NYSE:PFE) aimed at assessing the impact of mutations on different signaling pathways engaged by GPCRs. Pfizer has interest in GPCRs with potential therapeutic relevance and Domain Therapeutics will use its proprietary bioSensAll™ technology to define signaling signatures for each wild-type and mutant receptors.

Download PDF